Eli Lilly, Boehringer Ingelheim get approval to expand Jardiance, Synjardy labels to kids with type 2 diabetes

Eli Lil­ly and Boehringer In­gel­heim won FDA ap­proval to ex­pand em­pagliflozin’s la­bel to in­clude ado­les­cents with type 2 di­a­betes.

The SGLT2 in­hibitor, bet­ter known as Jar­diance, was first ap­proved to im­prove glycemic con­trol in adults with type 2 di­a­betes in 2014. On Tues­day, the drug un­der the brand name Jar­diance re­ceived an ex­pand­ed la­bel to low­er blood sug­ar in 10- to 17-year-old pa­tients with type 2 di­a­betes in con­junc­tion with di­et and ex­er­cise. It’s al­so now ap­proved in com­bi­na­tion with met­formin, the on­ly oth­er oral ther­a­py avail­able for chil­dren with type 2 di­a­betes, for the 10 to 17 age group, for which it will be mar­ket­ed as Syn­jardy.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN